X

Drug Profile

IK 412

Alternative Names: IK-412; KYN 412; Kynase

Latest Information Update: 24 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ikena Oncology
Class Antineoplastics; Hydrolases
Mechanism of Action Enzyme replacements; Kynurenine modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Discontinued Cancer

Most Recent Events

13 May 2024 IK 412 is available for licensing as of 13 May 2024 (Form 10K, December 2023)
13 May 2024 Discontinued - Preclinical for Cancer in USA (unspecified route)
15 Feb 2024 Ikena Oncology has patent protection for IK-412 kynurenine programme in the US

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com